HYFT — MindWalk Holdings Corp.

Summary of MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue reached CAD 4.2 million, a 52% increase from CAD 2.7 million in Q3 2025. This marks the third consecutive quarter of year-over-year revenue growth.
• U.S. Revenue: U.S. revenue doubled year-over-year to CAD 2.6 million, reflecting a strategic focus on the North American market.
• Gross Margin: Q3 gross margin was 59%, down from 65% in the prior year, but improved to 58% for the nine-month period compared to 53% last year.
• Net Loss: Q3 net loss from continuing operations was CAD 3.9 million, significantly reduced from CAD 22 million in Q3 2025, which included a large impairment charge.
• Cash Position: Ended the quarter with CAD 14.2 million in cash, with CAD 10.1 million used in operations year-to-date.

2. Strategic Updates and Business Highlights

• Pipeline Progress: Advanced three key programs (dengue, GLP-1, and influenza) towards data readouts.
• Lens AI Contract: Secured the first one-year enterprise contract for the Lens AI platform, transitioning part of revenue from project-based to recurring revenue.
• Commercial Expansion: Continued investment in U.S. commercial presence, particularly in Boston and Cambridge, to leverage growing demand for AI-driven drug discovery.
• B Cell LAMA Launch: Introduced a new nanobody discovery platform aimed at addressing challenges in bispecific antibody development.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated continued revenue growth driven by the adoption of the Lens AI platform and expansion of the client base.
• Pipeline Developments: Expecting significant data readouts from dengue and GLP-1 programs in the near term, which could enhance investor confidence and attract further partnerships.
• Asset-Level Financing: Engaging legal and financial advisers to structure financing vehicles for proprietary pipeline assets, which may support future growth.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: The decrease in gross margin from the previous year may raise concerns about cost management as the company scales.
• High Operating Expenses: Increased R&D and sales/marketing expenses reflect ongoing investments but could pressure profitability if revenue growth does not keep pace.
• Dependence on U.S. Market: Heavy reliance on the U.S. market for revenue growth may expose the company to regional economic fluctuations or regulatory changes.

5. Notable Q&A Insights

• Enterprise Contract Drivers: The decision by a major pharma client to sign a recurring contract was driven by successful past collaborations and the ability of Lens AI to deliver superior results compared to competitors.
• Future Contracts: While no specific timelines were provided for additional contracts, the rollout of Lens AI across a broader client base is expected to facilitate further conversions to the recurring model.
• Asset-Level Financing Independence: The company indicated that the financing for different programs (dengue, GLP-1, influenza) can progress independently, with current cash reserves sufficient to support ongoing operations until further financing is secured.

Overall, MindWalk Holdings Corp. reported strong revenue growth and strategic advancements while navigating challenges related to margins and operational expenses. The outlook remains positive with ongoing developments in their pipeline and commercial strategies.